EXPRESS MAIL NO.: EL6[illegible]210673US PATENT

#3/Re A MAY 4/2/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Stephen J. GARGER, *et al.*

Application Serial No. 09/993,059

Filed: November 13, 2001

For: **PRODUCTION OF LYSOSOMAL ENZYMES IN PLANTS BY TRANSIENT EXPRESSION**

Group Art Unit: 1656 38

Examiner: ~~Not Yet Assigned~~ Fox

Attorney's Docket No: 00801.0087.CPUS07

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

AMENDMENT

Clean Version of the Amended Specification and Claims

In the Specification:

The paragraph begining at page 24, line 9 should read:

"Gal-A is one of many proteins that require glycan site occupancy at N-linked sites to achieve proper folding and stability. The ability to successfully target the enzyme in Fabry patients is also likely to be glycosylation-dependent. This requirement presently limits the expression possibilities to eukaryotic cell types. Recombinant proteins synthesized in baculovirus and yeast expression systems are often hyperglycosylated and highly heterogeneous complicating the preparation of therapeutically effective glycoforms from these sources. The rGal-A synthesized in plants is a relatively homogeneous glycoform as analyzed by its SDS-PAGE electrophoretic mobility and comigrates with rGal-A produced purified from placenta (Fig. 3). The expression results (yield and purity) we have already presented are unprecedented in any eukaryote system for a glycosylated enzyme and are not likely to be achieved in the

A1